Bayer's Turnaround Thesis Faces a Fortnight of Tests

Bayer's stock faces key tests as positive Phase III data for Asundexian boosts growth hopes, but a major U.S. Supreme Court glyphosate case looms.

Bayer shares, having nearly doubled over the past year, are entering a critical two-week period where clinical promise meets legal and financial reality. The stock closed Friday at €41.10, trading precisely at its 50-day moving average—a technical signal of stability amid looming catalysts.

The most significant recent development comes from the company's pharmaceutical pipeline. The blood thinner Asundexian, a cornerstone of Bayer's post-patent future, has delivered pivotal Phase III results. Published in the New England Journal of Medicine, data shows the drug reduces strokes by 26% without an increased risk of bleeding—a critical clinical advantage that has limited broader use of previous anticoagulants. This provides the first robust scientific foundation for CEO Bill Anderson’s target of returning the pharma division to mid-single-digit growth from 2027 onward.

Analysts are taking note of the shifting landscape. Deutsche Bank has radically revised its price target for the DAX-listed conglomerate, lifting it from €23 to €43, though it maintains a "Hold" rating. Analyst Virginie Boucher-Ferte anticipates organic growth of nearly 4% in the upcoming quarterly report, driven primarily by the Crop Science division. She notes that triple-digit million-euro licensing revenues in agriculture are cushioning current pharmaceutical weakness, even as she forecasts a slight decline in the adjusted operating result for the first quarter.

The company's broader transformation is underway. Management views 2026 as the final year of significant headwinds from patent expiries for blockbusters Xarelto and Eylea. New drugs are already gaining traction: cancer treatment Nubeqa saw revenue surge 57% to €2.4 billion, while kidney drug Kerendia posted even steeper percentage growth. These successes, alongside Asundexian, form the basis for Anderson’s ambition to lift the division's operating margin toward 30% by 2030.

Financially, Bayer is making progress on debt reduction. Net financial debt fell by approximately 8.5% by the end of 2025 to just under €30 billion. The capital market has rewarded this consolidation, with the stock's 12-month gain standing at roughly 95% from a 52-week low of €21.02.

Immediate tests begin this week. On Monday, the market will scrutinize advance copies of speeches by CEO Anderson and Supervisory Board Chairman Norbert Winkeljohann for concrete details on restructuring and debt reduction. The virtual Annual General Meeting follows on Friday, where shareholders will vote on an unchanged dividend of €0.11 per share and new supervisory board elections.

Yet the most consequential event may be a legal one. On April 27, the U.S. Supreme Court will hear oral arguments in the pivotal Durnell case, a proceeding that could fundamentally redefine Bayer's future liability framework for glyphosate litigation. While Asundexian’s data sends a powerful signal about Bayer's scientific future, the decision in Washington remains the single largest open risk for investors. The outcome will determine whether the company's hard-won operational momentum can finally outpace its legal overhang.